



April 24, 2017

Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU[®] Tablets 100mg, a treatment agent for type 2 diabetes mellitus

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director: Masayuki Mitsuka) announced today that consolidated subsidiary Tai Tien Pharmaceuticals Co., Ltd. (Head Office: Taipei, Taiwan; General Manager: Hitoshi Kawabe) has received import and marketing permission for CANAGLU[®] Tablets 100mg (generic name: canagliflozin) for an indication of type 2 diabetes mellitus.

CANAGLU[®], which was discovered in Japan by Mitsubishi Tanabe Pharma, inhibits sodium glucose co-transporter 2 (SGLT2), a transporter involved in the reabsorption of glucose in the proximal renal tubules of the kidneys; suppresses the reabsorption of glucose; and promotes the excretion of excessive glucose into the urine, and as a result, lowers blood glucose.

The number of diabetes patients in Taiwan has been increasing in recent years, and that trend is expected to continue.

Through licensees, CANAGLU[®] has been approved in more than 70 countries around the world. Following Japan, Taiwan will be the second market in which CANAGLU[®] is sold by the Mitsubishi Tanabe Pharma Group.

Tai Tien Pharmaceuticals, which was established in 1987, has marketed such products as HERBESSER[®], CONCOR[®] (Japan name: MAINTATE[®]), and LIVALO[®]. Through the marketing of these products, Tai Tien Pharmaceuticals has built a foundation in the field of lifestyle diseases. Leveraging that foundation, the Group will provide CANAGLU[®] to patients with type 2 diabetes mellitus.

Moving forward, Mitsubishi Tanabe Pharma will continue working to implement business activities that facilitate the rapid delivery of better drugs to patients around the world more quickly.

<<For Details, Contact the Following Section>>

Corporate Communications Department

Tel +81-6-6205-5211